ANN ARBOR, Mich., July 31 /PRNewswire-FirstCall/ -- Esperion Therapeutics,
Inc. (Nasdaq: ESPR) today announced the pricing of its public offering of
4,000,000 shares of its common stock at $16.00 per share. The offering is
expected to close on August 6, 2003. All shares will be offered by the
Company. In addition, Esperion and certain selling stockholders have granted
the underwriters an option to purchase up to an additional 600,000 shares to
cover over-allotments, if any. Lehman Brothers Inc. is acting as bookrunner
and Citigroup Global Markets Inc., Needham & Company, Inc., U.S. Bancorp Piper
Jaffray Inc. and SG Cowen Securities Corporation are acting as co-managers.
An amended registration statement relating to these securities was filed
and declared effective by the Securities and Exchange Commission on July 31,
2003.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to commercialize
a novel class of drugs that focuses on a new treatment approach called "HDL
Therapy," which is based on the Company's understanding of high-density
lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse
lipid transport, or RLT, pathway by which excess cholesterol and other lipids
are removed from arteries and other tissues and are transported to the liver
for elimination from the body. Esperion's goal is to develop drugs that
exploit the beneficial functions of HDL within the RLT pathway. Esperion
currently has several product candidates under development for the treatment
of cardiovascular disease. Esperion is listed on the Nasdaq National Market
under the symbol "ESPR." For more information, visit http://www.esperion.com.
Safe Harbor Statement
The information contained in this press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are often identified by words such
as "hope," "may," "believe," "anticipate," "plan," "expect," "intend,"
"assume," and similar expressions. Forward-looking statements speak only as of
the date of this press release, reflect management's current expectations and
involve certain factors, such as risks and uncertainties, which may cause
actual results to be far different from those suggested by the Company's
forward-looking statements. These factors include, but are not limited to,
risks associated with: management's ability to successfully execute its
business strategies, including entering into any strategic partnerships or
other transactions; the progress and cost of development of the Company's
product candidates; the extent and timing of market acceptance of new products
developed by the Company or its competitors; dependence on third parties to
conduct clinical trials for these product candidates; the extent and timing of
regulatory approval, as desired or required, for the Company's product
candidates; the Company's dependence on licensing arrangements and strategic
relationships with third parties; clinical trials; manufacturing; the
Company's dependence on patents and proprietary rights; the procurement,
maintenance, enforcement and defense of the Company's patents and proprietary
rights; competitive conditions in the industry; business cycles affecting the
markets in which any of the Company's products may be sold; extraordinary
events and transactions; the timing and extent of the Company's financing
needs and the Company's access to funding, including through the equity
market; economic conditions generally or in various geographic areas; and
other factors. These factors are discussed in more detail in the Company's
filings with the Securities and Exchange Commission. The Company does not
intend to update any of these factors or to publicly announce the results of
any revisions to any of these forward-looking statements other than as
required under the federal securities laws.
Company Frank Thomas
Contact: VP, Finance and Investor Relations
Esperion Therapeutics, Inc.
(734) 222-1831
fthomas@esperion.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
CONTACT:
Frank Thomas, VP, Finance and Investor
Relations of Esperion Therapeutics, Inc., +1-734-222-1831,
fthomas@esperion.com
|
